- Biotechnology company Tiziana Life Sciences said it was speeding up the development of a treatment for the novel coronavirus.

The company said it was expediating the development of TZLS-501, a monoclonal antibody that could help patients with severe lung damage.

Tiziana said it planned to administer TZLS-501 'using a proprietary formulation technology'.

It had in 2017 entered into a worldwide license for composition-of-matter of TZLS-501 with Swiss company Novimmune.

At 9:11am: [LON:TILS] Tiziana Life Sciences Plc share price was +80.5p at 112.5p

Story provided by